Brevan Howard Capital Management’s Pacira BioSciences PCRX Stock Holding History

Brevan Howard Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,662	Closed	-$431K	–	2417
2025 Q4	$431K	Buy	16,662 +4,797	+40%	+$114K	0.01%	1185
2025 Q3	$306K	Sell	11,865 -15,732	-57%	-$386K	﹤0.01%	1555
2025 Q2	$660K	Buy	27,597 +19,495	+241%	+$491K	0.01%	1242
2025 Q1	$201K	Sell	8,102 -25,711	-76%	-$616K	0.01%	985
2024 Q4	$637K	Buy	+33,813	New	+$594K	0.02%	552
2024 Q2	–	Sell	-7,395	Closed	-$216K	–	1339
2024 Q1	$216K	Sell	7,395 -7,634	-51%	-$235K	0.02%	773
2023 Q4	$507K	Buy	+15,029	New	+$440K	0.05%	474

Other funds holding PCRX

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return